{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:17:49Z","timestamp":1786979869628,"version":"build-2736575974"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"19","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Microbiol Biotechnol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00253-019-10057-0","type":"journal-article","created":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T22:02:36Z","timestamp":1565560956000},"page":"7903-7916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Mycobacterium bovis BCG in metastatic melanoma therapy"],"prefix":"10.1007","volume":"103","author":[{"given":"Martha Lucia Ruiz","family":"Benitez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Bonnemann","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds Larr\u00e9","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle M.","family":"Schachtschneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Collares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4204-2500","authenticated-orcid":false,"given":"Fabiana K\u00f6mmling","family":"Seixas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"10057_CR1","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1001\/jama.292.22.2771","volume":"292","author":"NR Abbasi","year":"2004","unstructured":"Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, Kopf AW, Polsky D (2004) Early diagnosis of cutaneous melanoma. Jama 292:2771. https:\/\/doi.org\/10.1001\/jama.292.22.2771","journal-title":"Jama"},{"key":"10057_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molmed.2014.12.007","volume":"21","author":"C Abildgaard","year":"2015","unstructured":"Abildgaard C, Guldberg P (2015) Molecular drivers of cellular metabolic reprogramming in melanoma. Trends Mol Med 21:164\u2013171. https:\/\/doi.org\/10.1016\/j.molmed.2014.12.007","journal-title":"Trends Mol Med"},{"key":"10057_CR3","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/cncr.20166","volume":"100","author":"SS Agarwala","year":"2004","unstructured":"Agarwala SS, Neuberg D, Park Y, Kirkwood JM (2004) Mature results of a phase III randomized trial of Bacillus Calmette-Guerin (BCG) versus observation and BCG plus Dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on cancer stage I-III melanoma (E1673): a trial of the Eastern Coop. Cancer 100:1692\u20131698. https:\/\/doi.org\/10.1002\/cncr.20166","journal-title":"Cancer"},{"key":"10057_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/MOU.0000000000000088","volume":"24","author":"JJ Ahn","year":"2014","unstructured":"Ahn JJ, Ghandour RA, McKiernan JM (2014) New agents for Bacillus Calmette-Gu\u00e9rin-refractory nonmuscle invasive bladder cancer. Curr Opin Urol 24:540\u2013545. https:\/\/doi.org\/10.1097\/MOU.0000000000000088","journal-title":"Curr Opin Urol"},{"key":"10057_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-018-0397-8","volume":"6","author":"MR Albertini","year":"2018","unstructured":"Albertini MR (2018) The age of enlightenment in melanoma immunotherapy. J Immunother Cancer 6:4\u20137. https:\/\/doi.org\/10.1186\/s40425-018-0397-8","journal-title":"J Immunother Cancer"},{"key":"10057_CR6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.5858\/arpa.2013-0134-AO","volume":"138","author":"E Alegre","year":"2014","unstructured":"Alegre E, Sanmamed MF, Rodriguez C, Carranza O, Mart\u00edn-Algarra S, Gonz\u00e1lez \u00c1 (2014) Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med 138:828\u2013832. https:\/\/doi.org\/10.5858\/arpa.2013-0134-AO","journal-title":"Arch Pathol Lab Med"},{"key":"10057_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejcsup.2013.07.012","volume":"11","author":"Z Ali","year":"2013","unstructured":"Ali Z, Yousaf N, Larkin J (2013) Melanoma epidemiology, biology and prognosis. Eur J Cancer Suppl 11:81\u201391. https:\/\/doi.org\/10.1016\/j.ejcsup.2013.07.012","journal-title":"Eur J Cancer Suppl"},{"key":"10057_CR8","doi-asserted-by":"publisher","unstructured":"Aris M, Bravo AI, Barrio MM, Mordoh J (2015) Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine\u00a0: a case report 6:1\u20135. doi: https:\/\/doi.org\/10.3389\/fimmu.2015.00144","DOI":"10.3389\/fimmu.2015.00144"},{"key":"10057_CR9","doi-asserted-by":"publisher","unstructured":"Arnold M, Vries E de, Whiteman DC, Jemal A, Bray F, Parkin DM, Soerjomataram I (2018) Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012. 1314:1305\u20131314 . doi: https:\/\/doi.org\/10.1002\/ijc.31527","DOI":"10.1002\/ijc.31527"},{"key":"10057_CR10","unstructured":"Arulananda S, Blackley E, Cebon J (2018) Review of immunotherapy in melanoma. Cancer Forum 42:17\u201323"},{"key":"10057_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/181987","volume":"2012","author":"EJ Askeland","year":"2012","unstructured":"Askeland EJ, Newton MR, O\u2019Donnell MA, Luo Y (2012) Bladder cancer immunotherapy: BCG and beyond. Ther Adv Urol 2012:1\u201313. https:\/\/doi.org\/10.1155\/2012\/181987","journal-title":"Ther Adv Urol"},{"key":"10057_CR12","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/jco.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJSV (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199\u20136206. https:\/\/doi.org\/10.1200\/jco.2009.23.4799","journal-title":"J Clin Oncol"},{"key":"10057_CR13","doi-asserted-by":"publisher","unstructured":"Bandarchi B, Ma L, Navab R, Seth A, Rasty G (2010) From melanocyte to metastatic malignant melanoma. Dermatol Res Pract. https:\/\/doi.org\/10.1155\/2010\/583748","DOI":"10.1155\/2010\/583748"},{"key":"10057_CR14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/01.cji.0000208258.79005.5f","volume":"29","author":"MM Barrio","year":"2006","unstructured":"Barrio MM, de Motta PT, Kaplan J, von Euw EM, Bravo AI, Chacon RD, Mordoh J (2006) A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother 29:444\u2013454","journal-title":"J Immunother"},{"key":"10057_CR15","doi-asserted-by":"publisher","unstructured":"Bastian BC (2014) The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 9:239\u2013271. https:\/\/doi.org\/10.1146\/annurev-pathol-012513-104658","DOI":"10.1146\/annurev-pathol-012513-104658"},{"key":"10057_CR16","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1016\/j.vaccine.2009.08.044","volume":"27","author":"RG Bastos","year":"2009","unstructured":"Bastos RG, Borsuk S, Seixas FK, Dellagostin OA (2009) Recombinant Mycobacterium bovis BCG. Vaccine 27:6495\u20136503. https:\/\/doi.org\/10.1016\/j.vaccine.2009.08.044","journal-title":"Vaccine"},{"key":"10057_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/CMR.0b013e3283390711","volume":"20","author":"AY Bedikian","year":"2010","unstructured":"Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R (2010) A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 20:218\u2013226. https:\/\/doi.org\/10.1097\/CMR.0b013e3283390711","journal-title":"Melanoma Res"},{"key":"10057_CR18","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00253-012-4416-2","volume":"97","author":"KR Begnini","year":"2013","unstructured":"Begnini KR, Rizzi C, Campos VF, Borsuk S, Schultze E, Yurgel VC, Nedel F, Dellagostin OA, Collares T, Seixas FK (2013) Auxotrophic recombinant Mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitro. Appl Microbiol Biotechnol 97:1543\u20131552. https:\/\/doi.org\/10.1007\/s00253-012-4416-2","journal-title":"Appl Microbiol Biotechnol"},{"key":"10057_CR19","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1007\/s00253-015-6495-3","volume":"99","author":"KR Begnini","year":"2015","unstructured":"Begnini KR, Buss JH, Collares T, Seixas FK (2015) Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer. Appl Microbiol Biotechnol 99:3741\u20133754. https:\/\/doi.org\/10.1007\/s00253-015-6495-3","journal-title":"Appl Microbiol Biotechnol"},{"key":"10057_CR20","first-page":"488","volume":"23","author":"S Bhatia","year":"2009","unstructured":"Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23:488\u2013496","journal-title":"Oncology (Williston Park)"},{"key":"10057_CR21","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1128\/IAI.70.12.6549-6557.2002","volume":"70","author":"F Biet","year":"2002","unstructured":"Biet F, Kremer L, Wolowczuk I, Delacre M, Locht C (2002) Mycobacterium bovis BCG producing Interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 70:6549\u20136557. https:\/\/doi.org\/10.1128\/IAI.70.12.6549-6557.2002","journal-title":"Infect Immun"},{"key":"10057_CR22","doi-asserted-by":"crossref","unstructured":"Bishop JN, Bataille V, Gavin A, Lens M, Marsden J, Mathews TWC (2007) The prevention, diagnosis, referral and management of melanoma of the skin. Clin Med 7:283\u2013290","DOI":"10.7861\/clinmedicine.7-3-283"},{"key":"10057_CR23","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.tube.2007.07.006","volume":"87","author":"S Borsuk","year":"2007","unstructured":"Borsuk S, Mendum TA, Fagundes MQ, Michelon M, Cunha CW, McFadden J, Dellagostin OA (2007) Auxotrophic complementation as a selectable marker for stable expression of foreign antigens in Mycobacterium bovis BCG. Tuberculosis 87:474\u2013480. https:\/\/doi.org\/10.1016\/j.tube.2007.07.006","journal-title":"Tuberculosis"},{"key":"10057_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.clinbiochem.2012.12.011","volume":"46","author":"AC Bougnoux","year":"2013","unstructured":"Bougnoux AC, Solassol J (2013) The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma. Clin Biochem 46:518\u2013523. https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.12.011","journal-title":"Clin Biochem"},{"key":"10057_CR25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","volume":"92","author":"S Brandau","year":"2001","unstructured":"Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, Bhle A (2001) NK cells are essential for effective BCG immunotherapy. Int J Cancer 92:697\u2013702. https:\/\/doi.org\/10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","journal-title":"Int J Cancer"},{"key":"10057_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/PAT.0b013e328363b3bd","volume":"45","author":"JM Brandner","year":"2013","unstructured":"Brandner JM, Haass NK (2013) Melanoma\u2019s connections to the tumour microenvironment. Pathology 45:443\u2013452. https:\/\/doi.org\/10.1097\/PAT.0b013e328363b3bd","journal-title":"Pathology"},{"key":"10057_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4068\/cmj.2018.54.3.135","volume":"54","author":"L Broussard","year":"2018","unstructured":"Broussard L, Howland A, Ryu S, Song K, Norris D, Armstrong CA, Song PI (2018) Melanoma cell death mechanisms. Chonnam Med J 54:135. https:\/\/doi.org\/10.4068\/cmj.2018.54.3.135","journal-title":"Chonnam Med J"},{"key":"10057_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","volume":"36","author":"MK Callahan","year":"2018","unstructured":"Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M (2018) Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol 36:391\u2013398. https:\/\/doi.org\/10.1200\/JCO.2017.72.2850","journal-title":"J Clin Oncol"},{"key":"10057_CR29","doi-asserted-by":"publisher","unstructured":"Cananzi FCM, Mudan S, Dunne M, Belonwu N, Dalgleish AG (2013) Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma. Hum Vaccin Immunother 9:2427\u20132433. https:\/\/doi.org\/10.4161\/hv.25618","DOI":"10.4161\/hv.25618"},{"key":"10057_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00251-008-0303-5","volume":"60","author":"R Carretero","year":"2008","unstructured":"Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T (2008) Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60:439\u2013447. https:\/\/doi.org\/10.1007\/s00251-008-0303-5","journal-title":"Immunogenetics"},{"key":"10057_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/BF00205238","volume":"28","author":"N Cascinelli","year":"1989","unstructured":"Cascinelli N, R\u00fcmke P, MacKie R, Morabito A, Bufalino R (1989) The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Gu\u00e9rin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol Immunother 28:282\u2013286. https:\/\/doi.org\/10.1007\/BF00205238","journal-title":"Cancer Immunol Immunother"},{"key":"10057_CR32","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/CAD.0000000000000526","volume":"28","author":"M Cervinkova","year":"2017","unstructured":"Cervinkova M, Kucerova P, Cizkova J (2017) Spontaneous regression of malignant melanoma - Is it based on the interplay between host immune system and melanoma antigens? Anti-Cancer Drugs 28:819\u2013830. https:\/\/doi.org\/10.1097\/CAD.0000000000000526","journal-title":"Anti-Cancer Drugs"},{"key":"10057_CR33","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-04-0345","volume":"10","author":"PB Chapman","year":"2004","unstructured":"Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson DLP (2004) Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 10:4717\u20134723","journal-title":"Clin Cancer Res"},{"key":"10057_CR34","doi-asserted-by":"publisher","unstructured":"Chapman R, Stutz H, Jacobs W, Shephard E, Williamson AL (2013) Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T Cell response in mice. PLoS One 8:. doi: https:\/\/doi.org\/10.1371\/journal.pone.0071601","DOI":"10.1371\/journal.pone.0071601"},{"key":"10057_CR35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.adengl.2014.07.015","volume":"105","author":"C Ciudad-Blanco","year":"2014","unstructured":"Ciudad-Blanco C, Avil\u00e9s-Izquierdo JA, L\u00e1zaro-Ochaita P, Su\u00e1rez-Fern\u00e1ndez R (2014) Dermoscopic findings for the early detection of melanoma: an analysis of 200 cases. Actas Dermosifiliogr 105:683\u2013693. https:\/\/doi.org\/10.1016\/j.adengl.2014.07.015","journal-title":"Actas Dermosifiliogr"},{"key":"10057_CR36","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/1097-0142(19840215)53:4<833::AID-CNCR2820530402>3.0.CO;2-#","volume":"53","author":"JJ Costanzi","year":"1982","unstructured":"Costanzi JJ, Al-Sarraf M, Groppe C, Bottomley R, Fabian C, Neidhart JDD (1982) Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma a southwest oncology group study. Cancer 53:833\u2013836. https:\/\/doi.org\/10.1002\/1097-0142(19840215)53:4<833::AID-CNCR2820530402>3.0.CO;2-#","journal-title":"Cancer"},{"key":"10057_CR37","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/nejmoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Br\u00f6cker EB, LeBoit PE, Pinkel DBB (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135\u20132147. https:\/\/doi.org\/10.1056\/nejmoa050092","journal-title":"N Engl J Med"},{"key":"10057_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00152","volume":"5","author":"AC Da Costa","year":"2014","unstructured":"Da Costa AC, Nogueira SV, Kipnis A, Junqueira-Kipnis AP (2014) Recombinant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol 5:1\u20139. https:\/\/doi.org\/10.3389\/fimmu.2014.00152","journal-title":"Front Immunol"},{"key":"10057_CR39","doi-asserted-by":"publisher","unstructured":"Davar D, Tarhini AA, Kirkwood JM (2012) Adjuvant therapy for melanoma. Cancer J:192\u2013202. https:\/\/doi.org\/10.1097\/PPO.0b013e31824f118b","DOI":"10.1097\/PPO.0b013e31824f118b"},{"key":"10057_CR40","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/infdis\/jir592","volume":"204","author":"C Desel","year":"2011","unstructured":"Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, Kaufmann SHE (2011) Recombinant BCG \u0394ureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 204:1573\u20131584. https:\/\/doi.org\/10.1093\/infdis\/jir592","journal-title":"J Infect Dis"},{"key":"10057_CR41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0264-410X(02)00577-7","volume":"21","author":"G Dietrich","year":"2003","unstructured":"Dietrich G, Viret JF, Hess J (2003) Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments. Vaccine 21:667\u2013670. https:\/\/doi.org\/10.1016\/S0264-410X(02)00577-7","journal-title":"Vaccine"},{"key":"10057_CR42","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/JCO.2002.01.065","volume":"20","author":"LA DiFronzo","year":"2002","unstructured":"DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O\u2019Day SJ, Wanek LA, Stern SL, Morton DL (2002) Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 20:3242\u20133248. https:\/\/doi.org\/10.1200\/JCO.2002.01.065","journal-title":"J Clin Oncol"},{"key":"10057_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.juro.2016.02.3005","volume":"197","author":"NM Donin","year":"2017","unstructured":"Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K (2017) Immunotherapy for the treatment of urothelial carcinoma. J Urol 197:14\u201322. https:\/\/doi.org\/10.1016\/j.juro.2016.02.3005","journal-title":"J Urol"},{"key":"10057_CR44","doi-asserted-by":"publisher","unstructured":"Duda RB, Yang H, Dooley DD, Abu-jawdeh G (1995) Recombinant BCG therapy suppresses melanoma tumor growth 2:542\u2013549. doi: https:\/\/doi.org\/10.1007\/bf02307089","DOI":"10.1007\/bf02307089"},{"key":"10057_CR45","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3892\/mmr.2014.2306","volume":"10","author":"F Fang","year":"2014","unstructured":"Fang F, Ma J, Ni W, Wang F, Sun X, Li Y, Li Q, Xie F, Wang J, Zhai R, Liu Z, Gao S, Tai G (2014) MUC1 and maltose-binding protein recombinant fusion protein combined with Bacillus Calmette-Guerin induces MUC1-specific and nonspecific anti-tumor immunity in mice. Mol Med Rep 10:1056\u20131064. https:\/\/doi.org\/10.3892\/mmr.2014.2306","journal-title":"Mol Med Rep"},{"key":"10057_CR46","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3b","volume":"24","author":"MB Faries","year":"2017","unstructured":"Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL (2017) Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol 24:3991\u20134000. https:\/\/doi.org\/10.1245\/s10434-017-6072-3b","journal-title":"Ann Surg Oncol"},{"key":"10057_CR47","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1200\/JCO.2008.18.0554","volume":"27","author":"P Findeisen","year":"2009","unstructured":"Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S (2009) Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 27:2199\u20132208. https:\/\/doi.org\/10.1200\/JCO.2008.18.0554","journal-title":"J Clin Oncol"},{"key":"10057_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1741-7015-10-23","volume":"10","author":"L Finn","year":"2012","unstructured":"Finn L, Markovic SN, Joseph RW (2012) Therapy for metastatic melanoma\u00a0: the past, present, and future. BMC Med 10:23. https:\/\/doi.org\/10.1186\/1741-7015-10-23","journal-title":"BMC Med"},{"key":"10057_CR49","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1002\/cncr.25261","volume":"116","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, McArthur G (2010) BRAF, a target in melanoma. Cancer 116:4902\u20134913. https:\/\/doi.org\/10.1002\/cncr.25261","journal-title":"Cancer"},{"key":"10057_CR50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s002620050283","volume":"42","author":"T Fujimoto","year":"1996","unstructured":"Fujimoto T, Donnell MAO, Szilvasi A, Yang H, Duda RB (1996) Bacillus Calmette-Gu\u00e9rin plus interleukin-2 and\/or granulocyte\/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-g, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother 42:280\u2013284. https:\/\/doi.org\/10.1007\/s002620050283","journal-title":"Cancer Immunol Immunother"},{"key":"10057_CR51","doi-asserted-by":"publisher","unstructured":"Gallagher RP, Lee TK (2006) Adverse effects of ultraviolet radiation\u00a0: a brief review 92:119\u2013131. doi: https:\/\/doi.org\/10.1016\/j.pbiomolbio.2006.02.011","DOI":"10.1016\/j.pbiomolbio.2006.02.011"},{"key":"10057_CR52","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1158\/1055-9965.EPI-04-0564","volume":"14","author":"RP Gallagher","year":"2005","unstructured":"Gallagher RP, Spinelli JJ, Lee TK (2005) Tanning beds, sunlamps, and risk of cutaneous malignant melanoma\\r10.1158\/1055-9965.EPI-04-0564. Cancer Epidemiol Biomark Prev 14:562\u2013566. https:\/\/doi.org\/10.1158\/1055-9965.EPI-04-0564","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10057_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","volume":"16","author":"C Garbe","year":"2011","unstructured":"Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5\u201324. https:\/\/doi.org\/10.1634\/theoncologist.2010-0190","journal-title":"Oncologist"},{"key":"10057_CR54","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","volume":"6","author":"MJ Garnett","year":"2004","unstructured":"Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313\u2013319. https:\/\/doi.org\/10.1016\/j.ccr.2004.09.022","journal-title":"Cancer Cell"},{"key":"10057_CR55","doi-asserted-by":"publisher","first-page":"MMT07","DOI":"10.2217\/mmt-2017-0026","volume":"5","author":"G Gazz\u00e9","year":"2018","unstructured":"Gazz\u00e9 G (2018) Combination therapy for metastatic melanoma: a pharmacist\u2019s role, drug interactions & complementary alternative therapies. Melanoma Manag 5:MMT07. https:\/\/doi.org\/10.2217\/mmt-2017-0026","journal-title":"Melanoma Manag"},{"key":"10057_CR56","first-page":"1359","volume":"63","author":"BGA Goldstein","year":"2001","unstructured":"Goldstein BGA (2001) Diagnosis and management of malignant melanoma. Am Fam Physician 63:1359\u20131368","journal-title":"Am Fam Physician"},{"key":"10057_CR57","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.cmr.0000232299.44902.41","volume":"16","author":"R Gonzalez","year":"2006","unstructured":"Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO (2006) Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 16:521\u2013526. https:\/\/doi.org\/10.1097\/01.cmr.0000232299.44902.41","journal-title":"Melanoma Res"},{"key":"10057_CR58","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jamcollsurg.2004.10.032","volume":"200","author":"DH Gorski","year":"2005","unstructured":"Gorski DH, Alsina J, Mann B, Shih W, Kim HJ, Gabriel EM, Goydos JS, Germino FJ (2005) Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 200:362\u2013370. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2004.10.032","journal-title":"J Am Coll Surg"},{"key":"10057_CR59","doi-asserted-by":"publisher","unstructured":"Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R (2014) Genetic alterations and personalized medicine in melanoma: progress and future prospects J Natl Cancer Inst 106. doi: https:\/\/doi.org\/10.1093\/jnci\/djt435","DOI":"10.1093\/jnci\/djt435"},{"key":"10057_CR60","first-page":"23","volume":"59","author":"S Gurzu","year":"2018","unstructured":"Gurzu S, Beleaua MA, Jung I (2018) The role of tumor microenvironment in development and progression of malignant melanomas \u2013 a systematic review. Romanian J Morphol Embryol 59:23\u201328","journal-title":"Romanian J Morphol Embryol"},{"key":"10057_CR61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1023\/B:HIJO.0000032362.35354.bb","volume":"35","author":"NK Haass","year":"2004","unstructured":"Haass NK, Smalley KSM, Herlyn M (2004) The role of altered cell-cell communication in melanoma progression. J Mol Histol 35:309\u2013318. https:\/\/doi.org\/10.1023\/B:HIJO.0000032362.35354.bb","journal-title":"J Mol Histol"},{"key":"10057_CR62","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1080\/15384047.2015.1078024","volume":"18","author":"K Halder","year":"2017","unstructured":"Halder K, Banerjee S, Ghosh S, Bose A, Das S, Chowdhury BP, Majumdar S (2017) Mycobacterium indicus pranii (Mw) inhibits invasion by reducing matrix metalloproteinase (MMP-9) via AKT\/ERK-1\/2 and PKC\u03b1 signaling: a potential candidate in melanoma cancer therapy. Cancer Biol Ther 18:850\u2013862. https:\/\/doi.org\/10.1080\/15384047.2015.1078024","journal-title":"Cancer Biol Ther"},{"key":"10057_CR63","doi-asserted-by":"crossref","unstructured":"Hart PDA, Sutherland IAN (1977) BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life final report to the Medical Research Council. Public Health Rep 293\u2013295","DOI":"10.1136\/bmj.2.6082.293"},{"key":"10057_CR64","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Mart\u00edn-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358\u2013365. https:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X","journal-title":"Lancet"},{"key":"10057_CR65","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1574-695X.2009.00559.x","volume":"56","author":"D Hayashi","year":"2009","unstructured":"Hayashi D, Takii T, Fujiwara N, Fujita Y, Yano I, Yamamoto S, Kondo M, Yasuda E, Inagaki E, Kanai K, Fujiwara A, Kawarazaki A, Chiba T, Onozaki K (2009) Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) substrains. FEMS Immunol Med Microbiol 56:116\u2013128. https:\/\/doi.org\/10.1111\/j.1574-695X.2009.00559.x","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10057_CR66","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1345\/aph.1Q363","volume":"45","author":"Y Heakal","year":"2011","unstructured":"Heakal Y, Kester M, Savage S (2011) Vemurafenib (PLX4032): Un inhibidor de BRAF mutado disponible por v\u00eda oral para el tratamiento del melanoma metast\u00e1tico. Ann Pharmacother 45:1399\u20131405. https:\/\/doi.org\/10.1345\/aph.1Q363","journal-title":"Ann Pharmacother"},{"key":"10057_CR67","doi-asserted-by":"publisher","unstructured":"Hepner A, Salgues A, Garicochea B, Sahade M, Dos Anjos C, Sahade M, Camargo V, Garicochea B, Shoushtari A, Postow M, Fernandes GMR (2017) Treatment of advanced melanoma - a changing landscape. Rev Assoc Med Bras 63:814\u2013823. https:\/\/doi.org\/10.1590\/1806-9282.63.09.814","DOI":"10.1590\/1806-9282.63.09.814"},{"key":"10057_CR68","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0264-410X(00)00070-0","volume":"18","author":"H Himmelrich","year":"2000","unstructured":"Himmelrich H, Lo-Man R, Winter N, Guermonprez P, Sedlik C, Rojas M, Monnaie D, Gheorghiu M, Lagranderie M, Hofnung M, Gicquel B, Cl\u00e9ment JM, Leclerc C (2000) Immune responses induced by recombinant BCG strains according to level of production of a foreign antigen: MalE. Vaccine 18:2636\u20132647. https:\/\/doi.org\/10.1016\/S0264-410X(00)00070-0","journal-title":"Vaccine"},{"key":"10057_CR69","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:1558\u20131568. https:\/\/doi.org\/10.1016\/S1470-2045(16)30366-7","journal-title":"Lancet Oncol"},{"key":"10057_CR70","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Ch CL (2012) A landscape of driver mutations in melanoma. Cell 150:251\u2013263. https:\/\/doi.org\/10.1016\/j.cell.2012.06.024","journal-title":"Cell"},{"key":"10057_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2018.00178","volume":"8","author":"SA Hogan","year":"2018","unstructured":"Hogan SA, Levesque MP, Cheng PF (2018) Melanoma immunotherapy: next-generation biomarkers. Front Oncol 8:1\u201310. https:\/\/doi.org\/10.3389\/fonc.2018.00178","journal-title":"Front Oncol"},{"key":"10057_CR72","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1200\/JCO.2002.01.151","volume":"20","author":"EC Hsueh","year":"2002","unstructured":"Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O\u2019Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL (2002) Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549\u20134554. https:\/\/doi.org\/10.1200\/JCO.2002.01.151","journal-title":"J Clin Oncol"},{"key":"10057_CR73","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1245\/ASO.2004.02.018","volume":"11","author":"EC Hsueh","year":"2004","unstructured":"Hsueh EC, Famatiga E, Shu S, Ye X, Morton DL (2004) Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol 11:892\u2013899. https:\/\/doi.org\/10.1245\/ASO.2004.02.018","journal-title":"Ann Surg Oncol"},{"key":"10057_CR74","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.trivac.2014.08.002","volume":"3","author":"NT Iqbal","year":"2014","unstructured":"Iqbal NT, Hussain R (2014) Non-specific immunity of BCG vaccine: a perspective of BCG immunotherapy. Trials Vaccinol 3:143\u2013149. https:\/\/doi.org\/10.1016\/j.trivac.2014.08.002","journal-title":"Trials Vaccinol"},{"key":"10057_CR75","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.4049\/jimmunol.1502307","volume":"196","author":"E Kaufmann","year":"2016","unstructured":"Kaufmann E, Spohr C, Battenfeld S, De Paepe D, Holzhauser T, Balks E, Homolka S, Reiling N, Gilleron M, Bastian M (2016) BCG vaccination induces robust CD4+ T cell responses to Mycobacterium tuberculosis complex-specific lipopeptides in Guinea pigs. J Immunol 196:2723\u20132732. https:\/\/doi.org\/10.4049\/jimmunol.1502307","journal-title":"J Immunol"},{"key":"10057_CR76","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/CJI.0000000000000098","volume":"38","author":"N Kibbi","year":"2015","unstructured":"Kibbi N, Ariyan S, Faries M, Choi JN (2015) Treatment of in-transit melanoma with intralesional Bacillus Calmette-Gu\u00e9rin (BCG) and topical imiquimod 5% cream: a report of 3 cases. J Immunother 38:371\u2013375. https:\/\/doi.org\/10.1097\/CJI.0000000000000098","journal-title":"J Immunother"},{"key":"10057_CR77","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/CJI.0b013e31827457bd","volume":"35","author":"TB Kidner","year":"2012","unstructured":"Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, Faries MB (2012) Combined intralesional bacille calmette-gu\u00e9rin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716\u2013720. https:\/\/doi.org\/10.1097\/CJI.0b013e31827457bd","journal-title":"J Immunother"},{"key":"10057_CR78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.cir-13-0216","volume":"2","author":"H-J Kim","year":"2014","unstructured":"Kim H-J, Cantor H (2014) CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2:91\u201398. https:\/\/doi.org\/10.1158\/2326-6066.cir-13-0216","journal-title":"Cancer Immunol Res"},{"key":"10057_CR79","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clim.2014.10.005","volume":"155","author":"J Kleinnijenhuis","year":"2014","unstructured":"Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, van der Meer JW, van Crevel RNM (2014) BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol 155:213\u2013219. https:\/\/doi.org\/10.1016\/j.clim.2014.10.005","journal-title":"Clin Immunol"},{"key":"10057_CR80","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2004.09.023","volume":"41","author":"KF K\u00f6lmel","year":"2005","unstructured":"K\u00f6lmel KF, Grange JM, Krone B, Mastrangelo G, Rossi CR, Henz BM, Seebacher C, Botev IN, Niin M, Lambert D, Shafir R, Kokoschka EM, Kleeberg UR, Gefeller O, Pfahlberg A (2005) Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 41:118\u2013125. https:\/\/doi.org\/10.1016\/j.ejca.2004.09.023","journal-title":"Eur J Cancer"},{"key":"10057_CR81","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0022-5347(06)00264-3","volume":"175","author":"MP Koya","year":"2006","unstructured":"Koya MP, Simon MA, Soloway MS (2006) Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 175:2004\u20132010. https:\/\/doi.org\/10.1016\/S0022-5347(06)00264-3","journal-title":"J Urol"},{"key":"10057_CR82","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2217\/1750743X.1.2.281","volume":"1","author":"TP Kresowik","year":"2009","unstructured":"Kresowik TP, Griffith TS (2009) Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 1:281\u2013288. https:\/\/doi.org\/10.2217\/1750743X.1.2.281","journal-title":"Immunotherapy"},{"key":"10057_CR83","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13104-019-4086-6","volume":"12","author":"P Kumar","year":"2019","unstructured":"Kumar P, Bhaskar S (2019) Myeloid differentiation primary response protein 88 (MyD88)-deficient dendritic cells exhibit a skewed cytokine response to BCG. BMC Res Notes 12:12\u201315. https:\/\/doi.org\/10.1186\/s13104-019-4086-6","journal-title":"BMC Res Notes"},{"key":"10057_CR84","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.vaccine.2009.11.004","volume":"28","author":"MK Lalor","year":"2010","unstructured":"Lalor MK, Smith SG, Floyd S, Gorak-Stolinska P, Weir RE, Blitz R, Branson K, Fine PE, Dockrell HM (2010) Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine 28:1635\u20131641. https:\/\/doi.org\/10.1016\/j.vaccine.2009.11.004","journal-title":"Vaccine"},{"key":"10057_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00965","volume":"8","author":"RD Lardone","year":"2017","unstructured":"Lardone RD, Chan AA, Lee AF, Foshag LJ, Faries MB, Sieling PA, Lee DJ (2017) Mycobacterium bovis Bacillus Calmette\u2013Gu\u00e9rin alters melanoma microenvironment favoring antitumor T cell responses and improving M2 macrophage function. Front Immunol 8:1\u201314. https:\/\/doi.org\/10.3389\/fimmu.2017.00965","journal-title":"Front Immunol"},{"key":"10057_CR86","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jnci\/djy086","volume":"111","author":"M Lattanzi","year":"2019","unstructured":"Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim RH, Hernando E, Polsky D, Hanniford D, Shapiro R, Berman R, Pavlick AC, Wilson MA, Kirchhoff T, Weber JS, Zhong J, Osman I (2019) Primary melanoma histologic subtype: impact on survival and response to therapy. J Natl Cancer Inst 111:180\u2013188. https:\/\/doi.org\/10.1093\/jnci\/djy086","journal-title":"J Natl Cancer Inst"},{"key":"10057_CR87","first-page":"4286","volume":"52","author":"EC Lattime","year":"1992","unstructured":"Lattime EC (1992) Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res 52:4286\u20134290","journal-title":"Cancer Res"},{"key":"10057_CR88","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/00002371-200101000-00008","volume":"24","author":"R Lau","year":"2001","unstructured":"Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J (2001) Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66\u201378. https:\/\/doi.org\/10.1097\/00002371-200101000-00008","journal-title":"J Immunother"},{"key":"10057_CR89","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0039-6109(02)00204-9","volume":"83","author":"SPL Leong","year":"2003","unstructured":"Leong SPL (2003) Future perspectives on malignant melanoma. Surg Clin North Am 83:453\u2013456. https:\/\/doi.org\/10.1016\/S0039-6109(02)00204-9","journal-title":"Surg Clin North Am"},{"key":"10057_CR90","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/00002371-199903000-00008","volume":"22","author":"SP Leong","year":"1999","unstructured":"Leong SP, Enders-Zohr P, Zhou YM, Stuntebeck S, Habib FA, Allen RE Jr, Sagebiel RW, Glassberg AB, Lowenberg DWHF (1999) Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 22:166\u2013174. https:\/\/doi.org\/10.1097\/00002371-199903000-00008","journal-title":"J Immunother"},{"key":"10057_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-9-413","volume":"9","author":"AS Leung","year":"2008","unstructured":"Leung AS, Tran V, Wu Z, Yu X, Alexander DC, Gao GF, Zhu B, Liu J (2008) Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC Genomics 9:1\u201312. https:\/\/doi.org\/10.1186\/1471-2164-9-413","journal-title":"BMC Genomics"},{"key":"10057_CR92","doi-asserted-by":"publisher","unstructured":"Liang J, Teng X, Yuan X, Zhang Y, Shi C, Yue T, Zhou L, Li J, Fan X (2015) Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis. Mol Immunol 66:392\u2013401. https:\/\/doi.org\/10.1016\/j.molimm.2015.04.017","DOI":"10.1016\/j.molimm.2015.04.017"},{"key":"10057_CR93","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4161\/hv.5.2.7210","volume":"5","author":"J Liu","year":"2009","unstructured":"Liu J, Tran V, Leung AS, Alexander DC, Zhu B (2009) BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin 5:70\u201378. https:\/\/doi.org\/10.4161\/hv.5.2.7210","journal-title":"Hum Vaccin"},{"key":"10057_CR94","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3892\/etm.2017.4273","volume":"13","author":"W Liu","year":"2017","unstructured":"Liu W, Xu Y, Shen H, Yan J, Yang E, Wang H (2017) Recombinant bacille Calmette-Gu\u00e9rin coexpressing Ag85b-IFN-\u03b3 enhances the cell-mediated immunity in c57bl\/6 mice. Exp Ther Med 13:2339\u20132347. https:\/\/doi.org\/10.3892\/etm.2017.4273","journal-title":"Exp Ther Med"},{"key":"10057_CR95","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239\u20131246. https:\/\/doi.org\/10.1200\/JCO.2010.32.4327","journal-title":"J Clin Oncol"},{"key":"10057_CR96","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/sj\/bjc\/6600251","volume":"86","author":"M Lotem","year":"2002","unstructured":"Lotem M, Peretz T, Drize O, Gimmon Z, Ad El D, Weitzen R, Goldberg H, Ben David I, Prus D, Hamburger T, Shiloni E (2002) Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer 86:1534\u20131539. https:\/\/doi.org\/10.1038\/sj\/bjc\/6600251","journal-title":"Br J Cancer"},{"key":"10057_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8121985","volume":"2016","author":"M Lotem","year":"2016","unstructured":"Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T (2016) Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade. J Immunol Res 2016:1\u201312. https:\/\/doi.org\/10.1155\/2016\/8121985","journal-title":"J Immunol Res"},{"key":"10057_CR98","doi-asserted-by":"publisher","unstructured":"Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-delmaire T, Richmond A, Kelley MC, Vnencak-jones CL, Iafrate AJ, Sosman J, Pao W (2012) Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials 7: . doi: https:\/\/doi.org\/10.1371\/journal.pone.0035309","DOI":"10.1371\/journal.pone.0035309"},{"key":"10057_CR99","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","volume":"64","author":"AT Ludwig","year":"2004","unstructured":"Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O\u2019Donnell MA, Griffith TS (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Gu\u00e9rin-induced antitumor activity. Cancer Res 64:3386\u20133390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0374","journal-title":"Cancer Res"},{"key":"10057_CR100","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1046\/j.1365-2249.2001.01428.x","volume":"123","author":"Y Luo","year":"2001","unstructured":"Luo Y, Chen X, Han R, O\u2019Donnell MA (2001) Recombinant bacille Calmette-Gu\u00e9rin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123:264\u2013270. https:\/\/doi.org\/10.1046\/j.1365-2249.2001.01428.x","journal-title":"Clin Exp Immunol"},{"key":"10057_CR101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","volume":"21","author":"Y Luo","year":"2003","unstructured":"Luo Y, Chen X, O\u2019Donnell MA (2003) Role of Th1 and Th2 cytokines in BCG-induced IFN-\u03b3 production: cytokine promotion and simulation of BCG effect. Cytokine 21:17\u201326. https:\/\/doi.org\/10.1016\/S1043-4666(02)00490-8","journal-title":"Cytokine"},{"key":"10057_CR102","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2249.2004.02522.x","volume":"137","author":"Y Luo","year":"2004","unstructured":"Luo Y, Yamada H, Chen X, Ryan AA, Evanoff DP, Triccas JA, O\u2019Donnell MA (2004) Recombinant Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) expressing mouse IL-18 augmente Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 137:24\u201334. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02522.x","journal-title":"Clin Exp Immunol"},{"key":"10057_CR103","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1016\/j.vaccine.2018.04.025","volume":"36","author":"W Luo","year":"2018","unstructured":"Luo W, Qu Z, Zhang L, Xie Y, Luo F, Tan Y, Pan Q, Zhang XL (2018) Recombinant BCG::Rv2645 elicits enhanced protective immunity compared to BCG in vivo with induced ISGylation-related genes and Th1 and Th17 responses. Vaccine 36:2998\u20133009. https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.025","journal-title":"Vaccine"},{"key":"10057_CR104","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.critrevonc.2018.11.002","volume":"133","author":"C Luther","year":"2019","unstructured":"Luther C, Swami U, Zhang J, Milhem M, Zakharia Y (2019) Advanced stage melanoma therapies: detailing the present and exploring the future. Crit Rev Oncol Hematol 133:99\u2013111. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.11.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10057_CR105","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","volume":"22","author":"A Mantovani","year":"2010","unstructured":"Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231\u2013237. https:\/\/doi.org\/10.1016\/j.coi.2010.01.009","journal-title":"Curr Opin Immunol"},{"key":"10057_CR106","doi-asserted-by":"publisher","first-page":"194","DOI":"10.20892\/j.issn.2095-3941.2016.0020","volume":"13","author":"M Maruf","year":"2016","unstructured":"Maruf M, Brancato SJ, Agarwal PK (2016) Nonmuscle invasive bladder cancer: a primer on immunotherapyNonmuscle invasive bladder cancer: a primer on immunotherapy. Cancer Biol Med 13:194\u2013205. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0020","journal-title":"Cancer Biol Med"},{"key":"10057_CR107","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41419-017-0059-7","volume":"9","author":"G Mattia","year":"2018","unstructured":"Mattia G, Puglisi R, Ascione B, Malorni W, Car\u00e8 A, Matarrese P (2018) Cell death-based treatments of melanoma\u00a0: conventional treatments and new therapeutic strategies. Cell Death Dis 9:112. https:\/\/doi.org\/10.1038\/s41419-017-0059-7","journal-title":"Cell Death Dis"},{"key":"10057_CR108","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0190-9622(82)70072-6","volume":"6","author":"FL Meyskens Jr","year":"1982","unstructured":"Meyskens FL Jr (1982) Studies of retinoids in the prevention and treatment of cancer. J Am Acad Dermatol 6:824\u2013830. https:\/\/doi.org\/10.1016\/S0190-9622(82)70072-6","journal-title":"J Am Acad Dermatol"},{"key":"10057_CR109","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S1567-5769(03)00019-5","volume":"3","author":"MS Mitchell","year":"2003","unstructured":"Mitchell MS (2003) Immunotherapy as part of combinations for the treatment of cancer. Int Immunopharmacol 3:1051\u20131059. https:\/\/doi.org\/10.1016\/S1567-5769(03)00019-5","journal-title":"Int Immunopharmacol"},{"key":"10057_CR110","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1464-410X.2006.06026.x","volume":"97","author":"J Miyazaki","year":"2006","unstructured":"Miyazaki J, Kawai K, Oikawa T, Johraku A, Hattori K, Shimazui T, Akaza H (2006) Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Gu\u00e9rin through Toll-like receptor signalling. BJU Int 97:860\u2013864. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06026.x","journal-title":"BJU Int"},{"key":"10057_CR111","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","volume":"193","author":"A Morales","year":"2015","unstructured":"Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, Kamat AM (2015) Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Gu\u00e9rin. J Urol 193:1135\u20131143. https:\/\/doi.org\/10.1016\/j.juro.2014.09.109","journal-title":"J Urol"},{"key":"10057_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00625","volume":"8","author":"J Mordoh","year":"2017","unstructured":"Mordoh J, Pampena MB, Aris M, Blanco PA, Lombardo M, von Euw EM, Mac KS, Crow MY, Bravo AI, O\u2019Connor JM, Orlando AG, Ramello F, Levy EM, Barrio MM (2017) Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus Bacillus Calmette-Guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose Interferon alpha 2B in stages IIB, IIC, and III cutaneous melanoma patients: a single institution, randomized study. Front Immunol 8:1\u201315. https:\/\/doi.org\/10.3389\/fimmu.2017.00625","journal-title":"Front Immunol"},{"key":"10057_CR113","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/BF00205300","volume":"1","author":"DL Morton","year":"1976","unstructured":"Morton DL, Eilber FR, Holmes EC, Sparks FC, Ramming KP (1976) Present status of BCG immunotherapy of malignant melanoma. Cancer Immunol Immunother 1:93\u201398. https:\/\/doi.org\/10.1007\/BF00205300","journal-title":"Cancer Immunol Immunother"},{"key":"10057_CR114","doi-asserted-by":"publisher","first-page":"335S","DOI":"10.1038\/jid.1993.59","volume":"100","author":"G Murphy","year":"1993","unstructured":"Murphy G, Radu A, Kaminer M, Berd D (1993) Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy. J Invest Dermatol 100:335S\u2013341S. https:\/\/doi.org\/10.1038\/jid.1993.59","journal-title":"J Invest Dermatol"},{"key":"10057_CR115","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1073\/pnas.93.2.934","volume":"93","author":"PJ Murray","year":"1996","unstructured":"Murray PJ, Aldovini A, Young RA (1996) Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci 93:934\u2013939. https:\/\/doi.org\/10.1073\/pnas.93.2.934","journal-title":"Proc Natl Acad Sci"},{"key":"10057_CR116","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1442-2042.2006.01697.x","volume":"14","author":"M Naoe","year":"2007","unstructured":"Naoe M, Ogawa Y, Takeshita K, Morita J, Iwamoto S, Miyazaki A, Yoshida H (2007) Bacillus Calmette-Gu\u00e9rin-pulsed dendritic cells stimulate natural killer T cells and \u03b3\u03b4T cells. Int J Urol 14:532\u2013538. https:\/\/doi.org\/10.1111\/j.1442-2042.2006.01697.x","journal-title":"Int J Urol"},{"key":"10057_CR117","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tube.2012.08.003","volume":"93","author":"M Newton-Foot","year":"2013","unstructured":"Newton-Foot M, Gey Van Pittius NC (2013) The complex architecture of mycobacterial promoters. Tuberculosis 93:60\u201374. https:\/\/doi.org\/10.1016\/j.tube.2012.08.003","journal-title":"Tuberculosis"},{"key":"10057_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.01147","volume":"8","author":"NE Nieuwenhuizen","year":"2017","unstructured":"Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B, Grode L, Kaufmann SHE (2017) The recombinant bacille Calmette-Gu\u00e9rin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol 8:1\u20139. https:\/\/doi.org\/10.3389\/fimmu.2017.01147","journal-title":"Front Immunol"},{"key":"10057_CR119","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.1026","volume":"44","author":"SI Nikolaev","year":"2012","unstructured":"Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, Michielin O, Muehlethaler K, Speiser D, Beckmann JS, Xenarios I, Halazonetis TD, Jongeneel CV, Stevenson BJ, Antonarakis SE (2012) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44:133\u2013139. https:\/\/doi.org\/10.1038\/ng.1026","journal-title":"Nat Genet"},{"key":"10057_CR120","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1007\/s00253-017-8439-6","volume":"101","author":"TL Oliveira","year":"2017","unstructured":"Oliveira TL, Rizzi C, Dellagostin OA (2017) Recombinant BCG vaccines: molecular features and their influence in the expression of foreign genes. Appl Microbiol Biotechnol 101:6865\u20136877. https:\/\/doi.org\/10.1007\/s00253-017-8439-6","journal-title":"Appl Microbiol Biotechnol"},{"key":"10057_CR121","doi-asserted-by":"publisher","first-page":"346","DOI":"10.18553\/jmcp.2014.20.4.346","volume":"20","author":"AJ Olszanski","year":"2014","unstructured":"Olszanski AJ (2014) Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Pharm 20:346\u2013356. https:\/\/doi.org\/10.18553\/jmcp.2014.20.4.346","journal-title":"J Manag Care Pharm"},{"key":"10057_CR122","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/pcmr.12041","volume":"26","author":"JL Orgaz","year":"2013","unstructured":"Orgaz JL, Sanz-Moreno V (2013) Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell Melanoma Res 26:39\u201357. https:\/\/doi.org\/10.1111\/pcmr.12041","journal-title":"Pigment Cell Melanoma Res"},{"key":"10057_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.02531","volume":"9","author":"MB Pampena","year":"2018","unstructured":"Pampena MB, Cartar HC, Cueto GR, Levy EM, Blanco PA, Barrio MM, Mordoh J (2018) Dissecting the immune stimulation promoted by CSF-470 vaccine plus adjuvants in cutaneous melanoma patients: long term antitumor immunity and short term release of acute inflammatory reactants. Front Immunol 9:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2018.02531","journal-title":"Front Immunol"},{"key":"10057_CR124","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3978\/j.issn.2305-5839.2015.08.11","volume":"3","author":"M Potrony","year":"2015","unstructured":"Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S (2015) Update in genetic susceptibility in melanoma. Ann Transl Med 3:210. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.08.11","journal-title":"Ann Transl Med"},{"key":"10057_CR125","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.2005.08.034","volume":"23","author":"S Puig","year":"2005","unstructured":"Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, Gonz\u00e0lez U, Castel T, Campoy A, Herrero J, Mart\u00ed R, Brunet-Vidal J, Mil\u00e0 M (2005) Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 23:3043\u20133051. https:\/\/doi.org\/10.1200\/JCO.2005.08.034","journal-title":"J Clin Oncol"},{"key":"10057_CR126","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/(SICI)1097-0215(20000301)85:5<659::AID-IJC11>3.0.CO;2-5","volume":"85","author":"G Ragupathi","year":"2000","unstructured":"Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO (2000) Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85:659\u2013666. https:\/\/doi.org\/10.1002\/(SICI)1097-0215(20000301)85:5<659::AID-IJC11>3.0.CO;2-5","journal-title":"Int J Cancer"},{"key":"10057_CR127","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/0008-5472.CAN-12-1882","volume":"73","author":"G Redelman-Sidi","year":"2013","unstructured":"Redelman-Sidi G, Iyer G, Solit DB, Glickman MS (2013) Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. Cancer Res 73:1156\u20131167. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1882","journal-title":"Cancer Res"},{"key":"10057_CR128","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1158\/1078-0432.ccr-11-2323","volume":"18","author":"A Ribas","year":"2011","unstructured":"Ribas A, Gogas H, Flaherty KT, Middleton MR, Sondak VK, Kirkwood JM, Hersey P (2011) New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 18:336\u2013341. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-2323","journal-title":"Clin Cancer Res"},{"key":"10057_CR129","doi-asserted-by":"publisher","unstructured":"Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu W, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C (2016) Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma 1782:1600\u20131609. doi: https:\/\/doi.org\/10.1001\/jama.2016.4059","DOI":"10.1001\/jama.2016.4059"},{"key":"10057_CR130","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1590\/0074-02760160360","volume":"112","author":"C Rizzi","year":"2017","unstructured":"Rizzi C, Peiter AC, Oliveira TL, Seixas Neto ACP, Leal KS, Hartwig DD, Seixas FK, Borsuk S, Dellagostin OA (2017) Stable expression of Mycobacterium bovis antigen 85B in auxotrophic m. Bovis bacillus calmette-gu\u00e9rin. Mem Inst Oswaldo Cruz 112:123\u2013130. https:\/\/doi.org\/10.1590\/0074-02760160360","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10057_CR131","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","volume":"399","author":"R Roskoski","year":"2010","unstructured":"Roskoski R (2010) RAF protein-serine\/threonine kinases: structure and regulation. Biochem Biophys Res Commun 399:313\u2013317. https:\/\/doi.org\/10.1016\/j.bbrc.2010.07.092","journal-title":"Biochem Biophys Res Commun"},{"key":"10057_CR132","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/infdis\/jiu675","volume":"211","author":"H Saiga","year":"2015","unstructured":"Saiga H, Nieuwenhuizen N, Gengenbacher M, Koehler AB, Schuerer S, Moura-Alves P, Wagner I, Mollenkopf HJ, Dorhoi A, Kaufmann SHE (2015) The recombinant BCG \u0394ureC::hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation. J Infect Dis 211:1831\u20131841. https:\/\/doi.org\/10.1093\/infdis\/jiu675","journal-title":"J Infect Dis"},{"key":"10057_CR133","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4161\/cbt.28555","volume":"15","author":"M Sanlorenzo","year":"2014","unstructured":"Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S (2014) Melanoma immunotherapy. Cancer Biol Ther 15:665\u2013674. https:\/\/doi.org\/10.4161\/cbt.28555","journal-title":"Cancer Biol Ther"},{"key":"10057_CR134","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/annonc\/mdp253","volume":"20","author":"D Schadendorf","year":"2009","unstructured":"Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AMM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P (2009) Immunotherapy of distant metastatic disease. Ann Oncol 20:41\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdp253","journal-title":"Ann Oncol"},{"key":"10057_CR135","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"T Schumacher","year":"2015","unstructured":"Schumacher T, Schreiber R (2015) Neoantigens in cancer immunotherapy. Science 348:69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971","journal-title":"Science"},{"key":"10057_CR136","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863.gp100","volume":"364","author":"D Schwartzentruber","year":"2011","unstructured":"Schwartzentruber D, Lawson D, Richards J, Conry R, Miller D, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra K, White R, Gonzalez R, Kuzel T, Curti B, Leming P, Whitman E, Balkissoon J, Reintgen D, Kaufman H, Marincola F, Merino M, Rosenberg S, Choyke P, Vena D, Hwu P (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119\u20132127. https:\/\/doi.org\/10.1056\/NEJMoa1012863.gp100","journal-title":"N Engl J Med"},{"key":"10057_CR137","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","volume":"189","author":"S Secanella-Fandos","year":"2013","unstructured":"Secanella-Fandos S, Luquin M, Juli\u00e1n E (2013) Connaught and russian strains showed the highest direct antitumor effects of different bacillus calmette-gu\u00e9rin substrains. J Urol 189:711\u2013718. https:\/\/doi.org\/10.1016\/j.juro.2012.09.049","journal-title":"J Urol"},{"key":"10057_CR138","doi-asserted-by":"crossref","unstructured":"Seixas FK, Borsuk S, Fagundes MQ, Hartwig DD, Cerqueira GM, Dellagostin OA (2010) Stable expression of Leptospira interrogans antigens in. Biol Res 43:13\u201318. doi: \/S0716-97602010000100003","DOI":"10.4067\/S0716-97602010000100003"},{"key":"10057_CR139","doi-asserted-by":"publisher","unstructured":"Shinozaki M, O\u2019day SJ, Kitago M, Amersi F, Kuo C, Kim J, Wang H-J, Hoon DSB (2007) Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. The management of cutaneous melanoma continues to pose a 53:2068\u20132075 . doi: https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2120","DOI":"10.1158\/1078-0432.CCR-06-2120"},{"key":"10057_CR140","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.18632\/oncotarget.1892","volume":"5","author":"E Shtivelman","year":"2014","unstructured":"Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE (2014) Pathways and therapeutic targets in melanoma. Oncotarget 5:1701\u20131752. https:\/\/doi.org\/10.18632\/oncotarget.1892","journal-title":"Oncotarget"},{"key":"10057_CR141","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"10057_CR142","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2217\/mmt-2017-0018","volume":"4","author":"E Simeone","year":"2017","unstructured":"Simeone E, Ascierto PA (2017) Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Manag 4:175\u2013178. https:\/\/doi.org\/10.2217\/mmt-2017-0018","journal-title":"Melanoma Manag"},{"key":"10057_CR143","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1046\/j.1365-2567.1999.00702.x","volume":"96","author":"L Slobbe","year":"1999","unstructured":"Slobbe L, Lockhart E, O\u2019Donnell MA, Mackintosh C, De Lisle G, Buchan G (1999) An in vivo comparison of bacillus Calmette-Guerin (BCG) and cytokine- secreting BCG vaccines. Immunology 96:517\u2013523. https:\/\/doi.org\/10.1046\/j.1365-2567.1999.00702.x","journal-title":"Immunology"},{"key":"10057_CR144","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/107327481602300104","volume":"23","author":"S Sloot","year":"2016","unstructured":"Sloot S, Rashid OM, Sarnaik AA, Zager JS (2016) Developments in intralesional therapy for metastatic melanoma. Cancer Control 23:12\u201320. https:\/\/doi.org\/10.1177\/107327481602300104","journal-title":"Cancer Control"},{"key":"10057_CR145","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/01.cji.0000211334.06762.89","volume":"30","author":"FO Smith","year":"2007","unstructured":"Smith FO, Goff SL, Klapper JA, Levy C, Allen T, Mavroukakis SA, Rosenberg SA (2007) Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother 30:130. https:\/\/doi.org\/10.1097\/01.cji.0000211334.06762.89","journal-title":"J Immunother"},{"key":"10057_CR146","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/cmar.s64979","volume":"6","author":"N Srivastava","year":"2014","unstructured":"Srivastava N, McDermott D (2014) Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res 6:279\u2013289. https:\/\/doi.org\/10.2147\/cmar.s64979","journal-title":"Cancer Manag Res"},{"key":"10057_CR147","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng.1041","volume":"44","author":"MS Stark","year":"2012","unstructured":"Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, Chow D, Sereduk C, Niemi NM, Tang N, Ellis JJ, Reid J, Zismann V, Tyagi S, Muzny D, Newsham I, Wu Y, Palmer JM, Pollak T, Youngkin D, Brooks BR, Lanagan C, Schmidt CW, Kobe B, MacKeigan JP, Yin H, Brown KM, Gibbs R, Trent J, Hayward NK (2012) Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 44:165\u2013169. https:\/\/doi.org\/10.1038\/ng.1041","journal-title":"Nat Genet"},{"key":"10057_CR148","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1586\/era.11.163","volume":"11","author":"JH Stewart","year":"2011","unstructured":"Stewart JH, Levine EA (2011) Role of bacillus Calmette\u2013Gu\u00e9rin in the treatment of advanced melanoma. Expert Rev Anticancer Ther 11:1671\u20131676. https:\/\/doi.org\/10.1586\/era.11.163","journal-title":"Expert Rev Anticancer Ther"},{"key":"10057_CR149","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/bjd.12698","volume":"170","author":"RJ Sullivan","year":"2014","unstructured":"Sullivan RJ, Flaherty KT (2014) Major therapeutic developments and current challenges in advanced melanoma. Br J Dermatol 170:36\u201344. https:\/\/doi.org\/10.1111\/bjd.12698","journal-title":"Br J Dermatol"},{"key":"10057_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0362-6","volume":"6","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL (2018) An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer 6:1\u201323. https:\/\/doi.org\/10.1186\/s40425-018-0362-6","journal-title":"J Immunother Cancer"},{"key":"10057_CR151","doi-asserted-by":"publisher","unstructured":"Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Sto M, Jocham D, Bo A, Brandau S (2006) Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. 8250\u20138258. doi: https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1416","DOI":"10.1158\/0008-5472.CAN-06-1416"},{"key":"10057_CR152","doi-asserted-by":"publisher","unstructured":"Terando AM, Faries MB, Morton DL (2007) Vaccine therapy for melanoma: current status and future directions. Vaccine 25:B4-16. doi: https:\/\/doi.org\/10.1016\/j.vaccine.2007.06.033","DOI":"10.1016\/j.vaccine.2007.06.033"},{"key":"10057_CR153","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/imt.11.46","volume":"3","author":"P Triozzi","year":"2011","unstructured":"Triozzi P, Tuthill R, Borden E (2011) Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy 3:653\u2013671. https:\/\/doi.org\/10.2217\/imt.11.46","journal-title":"Immunotherapy"},{"key":"10057_CR154","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1245\/aso.2001.8.3.198","volume":"8","author":"GJ Tsioulias","year":"2001","unstructured":"Tsioulias GJ, Gupta RK, Tisman G, Hsueh EC, Essner R, Wanek LA, Morton DL (2001) Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol 8:198\u2013203. https:\/\/doi.org\/10.1245\/aso.2001.8.3.198","journal-title":"Ann Surg Oncol"},{"key":"10057_CR155","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1128\/IAI.68.12.6883-6890.2000","volume":"68","author":"S Tsuji","year":"2000","unstructured":"Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T (2000) Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Gu\u00e9rin: involvement of toll-like receptors. Infect Immun 68:6883\u20136890. https:\/\/doi.org\/10.1128\/IAI.68.12.6883-6890.2000","journal-title":"Infect Immun"},{"key":"10057_CR156","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/1535-7163.MCT-15-0335","volume":"15","author":"R Velmurugan","year":"2016","unstructured":"Velmurugan R, Challa DK, Ram S, Ober RJ, Ward ES (2016) Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells. Mol Cancer Ther 15:1879\u20131889. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0335","journal-title":"Mol Cancer Ther"},{"key":"10057_CR157","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/030089168407000107","volume":"70","author":"U Veronesi","year":"1984","unstructured":"Veronesi U, Aubert C, Bajetta E, Beretta G, Bonadonna G, Cascinelli N, De Marsillac J, Ikonopisov R, Kiss B, Krementz T, Lejeune F, Mechl Z, Milton G, Morabito A, Mulder P, Pawlicki P, Priario J, Rumke P, Sertoli R, Tomin R, Trapeznikov N, Wagner R (1984) Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guerin (BCG), and DTIC + Corynebacterium parvum in advanced malignant melanoma. Tumori 70:41\u201348. https:\/\/doi.org\/10.1177\/030089168407000107","journal-title":"Tumori"},{"key":"10057_CR158","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1046\/j.1365-3083.1996.d01-28.x","volume":"43","author":"N Wada","year":"1996","unstructured":"Wada N, Ohara N, Kameoka M, Nishino Y, Matsumoto S, Nishiyama T, Naito M, Yukitake H, Okada Y, Ikuta K, Yamada T (1996) Long-lasting immune response induced by recombinant bacillus Calmette-Gu\u00e9rin (BCG) secretion system. Scand J Immunol 43:202\u2013209. https:\/\/doi.org\/10.1046\/j.1365-3083.1996.d01-28.x","journal-title":"Scand J Immunol"},{"key":"10057_CR159","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, van den Eertwegh AJM, Robert C, Akerley W, Schadendorf D, Lutzky J, Weber JS, Hassel JC, Ottensmeier CH, Lorigan P, Hogg D, Peschel C, Haanen JB, O\u2019Day SJ, Gonzalez R, Vaubel JM, Hodi FS, Linette GP, Clark JI, Tian J, Weber RW, McDermott DF, Lebb\u00e9 C, Urba WJ, Nichol GM, Sosman JA, Hoos A, Quirt I, Yellin MJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"10057_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2017.00061","volume":"7","author":"J Yang","year":"2017","unstructured":"Yang J, Jones MS, Ramos RI, Chan AA, Lee AF, Foshag LJ, Sieling PA, Faries MB, Lee DJ (2017) Insights into local tumor microenvironment immune factors associated with regression of cutaneous melanoma metastases by Mycobacterium bovis Bacille Calmette\u2013Gu\u00e9rin. Front Oncol 7:1\u201313. https:\/\/doi.org\/10.3389\/fonc.2017.00061","journal-title":"Front Oncol"},{"key":"10057_CR161","first-page":"77","volume":"5","author":"TJ Yao","year":"1999","unstructured":"Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB (1999) Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 5:77\u201381","journal-title":"Clin Cancer Res"},{"key":"10057_CR162","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1517\/14712598.2010.485185","volume":"10","author":"S Yuan","year":"2010","unstructured":"Yuan S, Shi C, Liu L, Han W (2010) MUC1-based recombinant Bacillus Calmette\u2013Gu\u00e9rin vaccines as candidates for breast cancer immunotherapy. Expert Opin Biol Ther 10:1037\u20131048. https:\/\/doi.org\/10.1517\/14712598.2010.485185","journal-title":"Expert Opin Biol Ther"},{"key":"10057_CR163","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","volume":"86","author":"W Zhao","year":"2000","unstructured":"Zhao W, Schorey J, Bong-Mastek M, Ritchey J, Brown E, Ratliff T (2000) Role of a Bacillus Calmette\u2013Gu\u00e9rin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86:83\u201388","journal-title":"Int J Cancer"},{"key":"10057_CR164","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1586\/14760584.2015.1068124","volume":"14","author":"YQ Zheng","year":"2015","unstructured":"Zheng YQ, Naguib YW, Dong Y, Shi YC, Bou S, Cui Z (2015) Applications of Bacillus Calmette\u2013Gu\u00e9rin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy. Expert Rev Vaccines 14:1255\u20131275. https:\/\/doi.org\/10.1586\/14760584.2015.1068124","journal-title":"Expert Rev Vaccines"},{"key":"10057_CR165","doi-asserted-by":"publisher","unstructured":"Zhou Y, Zhao D, Yue R, Khan SH, Shah SZA, Yin X, Yang L, Zhang Z, Zhou X (2015) Inflammasomes-dependent regulation of IL-1\u03b2 secretion induced by the virulent Mycobacterium bovis Beijing strain in THP-1 macrophages. Antonie Van Leeuwenhoek, Journal of Microbiology 108:163\u2013171. https:\/\/doi.org\/10.1007\/s10482-015-0475-6","DOI":"10.1007\/s10482-015-0475-6"}],"container-title":["Applied Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-019-10057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00253-019-10057-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-019-10057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:04:20Z","timestamp":1744131860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00253-019-10057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":165,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10057"],"URL":"https:\/\/doi.org\/10.1007\/s00253-019-10057-0","relation":{},"ISSN":["0175-7598","1432-0614"],"issn-type":[{"value":"0175-7598","type":"print"},{"value":"1432-0614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}